GlassScriptPhysician profile
Christina M Cunningham
NPI 1003359308
$4,110.53
in general payments reported to CMS, 2019-2025
32 companies · $2,729 in 2025
The $2,729 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.51 · 2024: $1,357 · 2025: $2,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,822 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,822.05 |
| Education | $263.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $501.01 | 2024-2025 | Kisunla, Emgality, Reyvow |
| Abbvie INC. | $431.80 | 2024-2025 | |
| Harmony Biosciences LLC | $413.09 | 2024-2025 | |
| Eisai INC. | $374.37 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $329.61 | 2024-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $286.59 | 2024-2025 | Xcopri |
| Lundbeck LLC | $266.67 | 2024-2025 | Vyepti |
| Pfizer INC. | $236.35 | 2024-2025 | |
| Argenx US, INC. | $145.86 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $137.23 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $97.68 | 2024-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $95.39 | 2024-2025 | Rexulti |
| Livanova USA, INC. | $76.34 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Biotech, INC. | $73.54 | 2025 | |
| Biogen, INC. | $70.95 | 2024-2025 | Vumerity, Tysabri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $66.15 | 2024-2025 | Gocovri |
| Ucb, INC. | $62.25 | 2024-2025 | Rystiggo |
| Jazz Pharmaceuticals INC. | $56.28 | 2024-2025 | |
| Ge Healthcare | $50.83 | 2024-2025 | |
| Catalyst Pharmaceuticals, INC. | $48.28 | 2024 | |
| Neurocrine Biosciences, INC. | $45.50 | 2024-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $42.56 | 2024 | Nuplazid |
| Merz Pharmaceuticals, LLC | $38.35 | 2025 | Inbrija, Xeomin |
| Astrazeneca Pharmaceuticals LP | $24.51 | 2021 | |
| Emd Serono, INC. | $21.32 | 2025 | |
| Amneal Pharmaceuticals LLC | $20.63 | 2025 | Crexont |
| Cala Health, INC. | $20.08 | 2025 | Cala Kiq |
| Neurelis, INC. | $16.79 | 2025 | Valtoco |
| Axsome Therapeutics, INC. | $16.05 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $15.82 | 2024 | Hyqvia |
| Tanabe Pharma America, INC. | $14.36 | 2025 | Radicava |
| Idorsia Pharmaceuticals US INC | $14.29 | 2025 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.